News Release

May 13, 2021
JCR Pharmaceuticals Co., Ltd.

Translation

Notice of Distribution of Retained Earnings

May 13 -- JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; "JCR") announced that its Board of Directors resolved at a meeting today to distribute retained earnings (term-end dividend) with the record date being March 31, 2021.

1. Details of dividends

	Amount decided	Latest forecast for dividend (Released on May 12, 2020)	Actual result for previous fiscal year (ended March 31, 2020)
Record date	March 31, 2021	March 31, 2021	March 31, 2020
Dividends per share*	7.50 yen	4.50 yen	17.00 yen
Total amount of dividends	929 million yen	-	525 million yen
Effective date	June 24, 2021	-	June 25, 2020
Dividend resource	Retained earnings	-	Retained earnings

*JCR conducted a four-for-one stock split of our common stock on October 1, 2020. The actual result for previous fiscal year are the actual amount of dividends before the stock split.

2. Reasons for the revision

JCR celebrated the 45th anniversary of our founding on September 13, 2020. JCR recognizes and appreciates the fact that this milestone was made possible because of the many years of support received from its stakeholders.

Therefore, we have determined to pay a commemorative dividend of 0.50 yen per share to mark this milestone and to express its appreciation to all of its shareholders.

Also, in the fiscal year ended March 31, 2021, we achieved record high business performance. As such, we have determined to pay ordinary dividend of 7.00 yen per share, 2.50 yen higher than the latest forecast of the fiscal year.

As a result, the year-end dividend for the fiscal year ended March 31, 2021 will be 7.50yen per share.

3. (Reference) Details of annual dividends**

	Dividend per share		
	Interim (End of 2nd quarter)	Year-end	Total
Fiscal year ended March 31, 2021	18.00 yen	Ordinary dividend 7.00 yen Commemorative dividend 0.50yen Total 7.50yen (Total 30.00 yen)	(Ordinary dividend 46.00 yen) (Commemorative dividend 2.00yen) (Total 48.00 yen)
Actual result for the year ended March 31, 2020	15.00 yen	17.00 yen	32.00 yen

**JCR conducted a four-for-one stock split of our common stock on October 1, 2020. The actual result for the year ended March 31, 2020 and the interim of the fiscal year ended March 31, 2021 are the actual amount of dividends before the stock split. The annual dividend per share of the fiscal year ended March 31, 2021 is not stated because the amounts cannot be simply combined due to the conducting of the stock split. Figures in parentheses in the year-end and the annual dividend per share of the fiscal year ended March 31, 2021 are before conversion to a stock split for reference.

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 45-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II (Hunter syndrome), Pompe disease, and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit https://www.jcrpharm.co.jp/en/site/en/.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as "believe," "estimate," "anticipate," "intend," "plan," "will," "would," "target" and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Contact:
Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jcrpharm.co.jp

###